Shimomatsuya Takumi, Mitsudou Yuko, Nakamura Tomoaki, Yonezawa Kei, Shiraishi Susumu, Fujino Mitsuhiro, Maruhashi Kazuhiro
Dept. of Surgery, Nagahama Red Cross Hospital.
Gan To Kagaku Ryoho. 2007 Jul;34(7):1139-41.
A 55-year-old woman underwent total mastectomy and axillary lymphnode dissection in 2001. Widespread lymphnode metastasis was found histologically (26/33). Neither PgR nor ER was positive. She underwent an AC regimen and paclitaxel chemotherapy. As CEA began to rise in 2002, she was given paclitaxel and docetaxel chemotherapy sequentially. As CEA rose again in 2004, capecitabine was begun. Painful erythema of the palms and soles of the feet appeared at the end of the second cycle. After admission, severe bone marrow suppression and jaundice were found. The bilateral hands, palms and soles of the feet became bullous and erosive with desquamation. The erosive lesions began to heal with epithelization in the third week. After general conditions had improved, capecitabine was restarted at a reduced dose. This patient had continued taking capecitabine even though she noticed the occurrence of the adverse effect. Patients and doctors must share confidential information when performing chemotherapy at the outpatient clinic.
一名55岁女性于2001年接受了全乳切除术及腋窝淋巴结清扫术。组织学检查发现广泛淋巴结转移(26/33)。孕激素受体(PgR)和雌激素受体(ER)均为阴性。她接受了AC方案及紫杉醇化疗。2002年癌胚抗原(CEA)开始升高,她先后接受了紫杉醇和多西他赛化疗。2004年CEA再次升高,开始使用卡培他滨。在第二个疗程结束时出现了手足掌疼痛性红斑。入院后,发现严重骨髓抑制和黄疸。双侧手、手掌和足底出现水疱、糜烂及脱屑。糜烂性病变在第三周开始上皮化愈合。一般情况改善后,以减量重新开始使用卡培他滨。尽管该患者注意到了不良反应的发生,但仍继续服用卡培他滨。在门诊进行化疗时,患者和医生必须共享保密信息。